Vimarsana
Biggest News Aggregation in the World

Page 8 - History Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from History Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In History Study Today - Breaking & Trending Today

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne ... - Vimarsana News

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne ... Santhera Pharmaceuticals Holding AGApril 28, 2021 GMT Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years ...

Source: apnews.com
Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy - Vimarsana News

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy se in , - y with other steroids . A sequence of studies investigated the safety, tolerability and long-term treatment benefit with vamorolone and provide open-label data in a total of 46 patients with DMD, aged 4 to up to 10 years (start/end of treatment), of which 41 (89%) completed a 2.5 years treatment period. 48 participants initially completed a two-week multiple ascending dose trial VBP15-002 [1], 46 of whom entered the open-label 6-month exte...

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy - Vimarsana News

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years in decline for time to stand (TTSTAND) velocity, and confirm safety and tolerability benefits of vamorolone over the 2.5-year follow u...

Bertrand Might: Life, legacy and next steps - Vimarsana News

Bertrand Might: Life, legacy and next steps

Bertrand Might: Life, legacy & next steps December 9th 2007 - October 23rd 2020 Established initially as a memorial after Bertrand “Buddy” Might’s sudden passing on October 23rd 2020 at the age of 12, this page now serves to remember him as a person and also to coordinate and catalyze activities that honor his legacy, such as the newly formed Bertrand Might Endowment for Hope. As a step toward building his active legacy, as his father and in the spirit of the mission he gave me in life, I’ve begun publishing articles on this site related to precision medicine. The very first is The Al...

Source: might.net